• Go to navigation
  • Go to content
AstraZeneca

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca United States

Main navigation

  • Home
  • Our medicines
  • Diseases and conditions
  • Community support
  • Help affording your medicines
  • Research & development
  • Healthcare professionals
  • Careers
  • About AstraZeneca US
    • Our company
    • AZ on the issues
    • Investors
    • Responsible business
    • Newsroom
      • All news
      • Corporate news
      • Financial news
      • Product news
      • Research news
      • Media resources
    • US web sites
    • Social media sites
    • Contact us

You are here

  • Home
  • About AstraZeneca US
  • Newsroom
  • News

The following shows headlines of all news articles published within 12-months, starting from most recent.

  • Pages
  • 1
  • 2
  • Next

Your search for 'crestor' produced 13 results. The area of search was 'All news'

    • Feb 8, 2010
    • US FDA approves new indication for CRESTOR® (rosuvastatin calcium)  
    • Dec 15, 2009
    • Favorable vote from FDA Advisory Committee on benefit/risk of CRESTOR® (rosuvastatin calcium) in JUPITER study  
    • Dec 11, 2009
    • Advisory Committee briefing materials for CRESTOR® sNDA available on US FDA web site  
    • Nov 17, 2009
    • CRESTOR® reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study  
    • Oct 16, 2009
    • U.S. Food and Drug Administration approves CRESTOR® for use in pediatric patients with heterozygous familial hypercholesterolemia  
    • Sep 1, 2009
    • AstraZeneca encourages all Americans to get their cholesterol checked during National Cholesterol Education Month in September  
    • Aug 31, 2009
    • CRESTOR® reduced risk of cardiovascular events in elderly patients in new analysis of JUPITER  
    • Jun 4, 2009
    • AstraZeneca and Abbott extend relationship to include co-promotion of TRILIPIX® (fenofibric acid)  
    • Jun 4, 2009
    • AstraZeneca and Abbott submit New Drug Application to the FDA for CERTRIAD™, an investigational treatment for mixed dyslipidemia  
    • Mar 30, 2009
    • Patients receiving hemodialysis for treatment of end stage renal disease did not benefit from statin therapy in the AURORA study  
  • Pages
  • 1
  • 2
  • Next

Page tools

  • Print
  • Bookmark this page
  • Subscribe to RSS news feed

Stay connected with us

Stay connected with us on our social media sites

  • Stay connected with us on our social media sites

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2010